CIK 0001439222 · Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-01 | Jones Cecilia Chief Financial Officer | Option exercise · Restricted stock units 10b5-1 | −2,000 | 4,000 | ||
| 2024-03-01 | Washburn Theodore James Jr. Principal Accounting Officer | Option exercise 10b5-1 | +777 | 3,663 | ||
| 2024-03-01 | Washburn Theodore James Jr. Principal Accounting Officer | Option exercise 10b5-1 | +2,350 | 5,718 | ||
| 2024-03-01 | Washburn Theodore James Jr. Principal Accounting Officer | Grant or award · Restricted stock units 10b5-1 | +7,350 | 7,350 | ||
| 2024-03-01 | Washburn Theodore James Jr. Principal Accounting Officer | Option exercise · Restricted stock units 10b5-1 | −777 | 777 | ||
| 2024-03-01 | Washburn Theodore James Jr. Principal Accounting Officer | Option exercise · Restricted stock units 10b5-1 | −2,350 | 4,700 | ||
| 2024-03-01 | Goff Brian Chief Executive Officer | Option exercise 10b5-1 | +8,500 | 57,936 | ||
| 2024-03-01 | Goff Brian Chief Executive Officer | Grant or award · Restricted stock units 10b5-1 | +54,000 | 54,000 | ||
| 2024-03-01 | Goff Brian Chief Executive Officer | Grant or award · Stock options (right to buy) 10b5-1 | +195,500 | 195,500 | ||
| 2024-03-01 | Goff Brian Chief Executive Officer | Option exercise · Restricted stock units 10b5-1 | −8,500 | 17,000 | ||
| 2024-03-01 | Burns James William Chief Legal Officer | Option exercise 10b5-1 | +3,834 | 35,811 | ||
| 2024-03-01 | Burns James William Chief Legal Officer | Option exercise 10b5-1 | +4,000 | 38,518 | ||
| 2024-03-01 | Burns James William Chief Legal Officer | Grant or award · Restricted stock units 10b5-1 | +17,000 | 17,000 | ||
| 2024-03-01 | Burns James William Chief Legal Officer | Grant or award · Stock options (right to buy) 10b5-1 | +60,000 | 60,000 | ||
| 2024-03-01 | Burns James William Chief Legal Officer | Option exercise · Restricted stock units 10b5-1 | −3,834 | 3,833 | ||
| 2024-03-01 | Burns James William Chief Legal Officer | Option exercise · Restricted stock units 10b5-1 | −4,000 | 8,000 | ||
| 2024-03-01 | Milanova Tsveta Chief Commercial Officer | Grant or award · Restricted stock units | +17,000 | 17,000 | ||
| 2024-03-01 | Milanova Tsveta Chief Commercial Officer | Grant or award · Stock options (right to buy) | +60,000 | 60,000 | ||
| 2024-02-27 | Schenkein David P Director | Option exercise | +11,858 | $31.64 | $375K | 134,712 |
| 2024-02-27 | Schenkein David P Director | Sale | −11,858 | $33.60 | $398K | 122,854 |
Page 23 of 48 · 941 trades